UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome

Journal of viral hepatitis, 2018-02, Vol.25 (2), p.214-215

2018

Volltextzugriff (PDF)

Steady-State Pharmacokinetics of Sofosbuvir and Velpatasvir in HCV-Infected Subjects without Cirrhosis, with Compensated Cirrhosis, or with Decompensated Cirrhosis in the Phase 3 Astral Studies

Journal of hepatology, 2016, Vol.64 (2), p.S614-S614

2016

Volltextzugriff (PDF)

Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination

Journal of hepatology, 2016, Vol.64 (2), p.S613-S614

2016

Volltextzugriff (PDF)

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment

Journal of hepatology, 2015-04, Vol.62, p.S590-S591

2015

Volltextzugriff (PDF)

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection

Drug metabolism and disposition, 2018-08, Vol.46 (8), p.1212-1225

2018

Volltextzugriff (PDF)

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

Journal of hepatology, 2014-04, Vol.60 (1), p.S317-S317

2014

Volltextzugriff (PDF)

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S46-S46

2014

Volltextzugriff (PDF)

FRI-168 - Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination

Journal of hepatology, 2016, Vol.64 (2), p.S613-S614

2016

Volltextzugriff (PDF)

FRI-169 - Steady-State Pharmacokinetics of Sofosbuvir and Velpatasvir in HCV-Infected Subjects without Cirrhosis, with Compensated Cirrhosis, or with Decompensated Cirrhosis in the Phase 3 Astral Studies

Journal of hepatology, 2016, Vol.64 (2), p.S614-S614

2016

Volltextzugriff (PDF)

New analytical techniques to facilitate preformulation screening in propellant systems

International journal of pharmaceutics, 2007-08, Vol.340 (1), p.223-229

2007

Volltextzugriff (PDF)

Application of USP Inlet Extensions to the TSI Impactor System 3306/3320 Using HFA 227 Based Solution Metered Dose Inhalers

Drug development and industrial pharmacy, 2005-01, Vol.31 (10), p.977-985

2005

Volltextzugriff (PDF)

Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: Solution Metered Dose Inhalers

Drug development and industrial pharmacy, 2004-01, Vol.30 (8), p.859-868

2004

Volltextzugriff (PDF)

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

The New England journal of medicine, 2021-11, Vol.385 (21), p.1941-1950

2021

Volltextzugriff (PDF)

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Antimicrobial agents and chemotherapy, 2024-04, Vol.68 (4), p.e0127323

2024

Volltextzugriff (PDF)

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

CPT: pharmacometrics and systems pharmacology, 2023-06, Vol.12 (6), p.853-864

2023

Volltextzugriff (PDF)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Open forum infectious diseases, 2023-08, Vol.10 (8), p.ofad354-ofad354

2023

Volltextzugriff (PDF)

Antibody therapy reverses biological signatures of COVID-19 progression

Cell reports. Medicine, 2022-08, Vol.3 (8), p.100721-100721, Article 100721

2022

Volltextzugriff (PDF)

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols

American journal of health-system pharmacy, 2005-11, Vol.62 (21), p.2271-2277

2005

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome

Steady-State Pharmacokinetics of Sofosbuvir and Velpatasvir in HCV-Infected Subjects without Cirrhosis, with Compensated Cirrhosis, or with Decompensated Cirrhosis in the Phase 3 Astral Studies

Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

FRI-168 - Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination

FRI-169 - Steady-State Pharmacokinetics of Sofosbuvir and Velpatasvir in HCV-Infected Subjects without Cirrhosis, with Compensated Cirrhosis, or with Decompensated Cirrhosis in the Phase 3 Astral Studies

New analytical techniques to facilitate preformulation screening in propellant systems

Application of USP Inlet Extensions to the TSI Impactor System 3306/3320 Using HFA 227 Based Solution Metered Dose Inhalers

Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: Solution Metered Dose Inhalers

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Antibody therapy reverses biological signatures of COVID-19 progression

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols

Intramuscular Versus Intravenous SARS-CoV-2 Neutralising Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomised Non-Inferiority Clinical Trial

Suchergebnisse filtern